K Number
K152970
Device Name
Dynarex Xeroform Petrolatum Dressing
Date Cleared
2016-10-03

(361 days)

Product Code
Regulation Number
N/A
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
Dynarex Xeroform Petrolatum Dressing is intended for use as a primary contact layer in dressing wounds such as lacerations, skin graft recipient sites, newly sutured wounds, abrasions, and minor or partial thickness burns. It may also be used as an initial layer in dressing surgical wounds with light exudate.
Device Description
The Dynarex Xeroform Petrolatum Dressing is a sterile, single use, non-adherent dressing consisting of non-woven absorbent gauze saturated with Xeroform with 3% Bismuth Tribromophenate in a petrolatum blend. Packaged in paper metalized chevron pouches and available in Sizes: 2" x 2" ( Item #: 3051), 1" x 8" ( Item #: 3052), 4" x 4" ( Item #: 3053), 5" x 9" ( Item #: 3054). Dynarex Xeroform Petrolatum Dressing gauze is a type of medical dressing and has ingredients finely wovens mesh medical gauze infused with a blend of petrolatum and 3% Bismuth Tribromophenate.
More Information

Not Found

No
The device description and intended use clearly describe a traditional wound dressing with no mention of AI or ML capabilities.

No
The device is a dressing used in wound care, which primarily acts as a barrier or protective layer and does not actively contribute to the healing process in a therapeutic manner.

No
This device is a wound dressing used for treating lacerations, burns, and surgical wounds, not for diagnosing medical conditions.

No

The device description clearly describes a physical medical dressing made of gauze saturated with a petrolatum blend, which is a hardware component.

Based on the provided information, the Dynarex Xeroform Petrolatum Dressing is not an IVD (In Vitro Diagnostic) device.

Here's why:

  • Intended Use: The intended use clearly describes the device as a dressing for wounds applied directly to the body. IVD devices are used to examine specimens (like blood, urine, or tissue) outside of the body to provide information about a person's health.
  • Device Description: The description details a sterile dressing made of gauze and a petrolatum blend. This is consistent with a topical medical device, not a diagnostic test.
  • Lack of IVD Characteristics: There is no mention of analyzing biological samples, performing tests, or providing diagnostic information.

Therefore, the Dynarex Xeroform Petrolatum Dressing falls under the category of a medical device used for wound care, not an In Vitro Diagnostic device.

N/A

Intended Use / Indications for Use

Dynarex Xeroform Petrolatum Dressing is intended for use as a primary contact layer in dressing wounds such as lacerations, skin graft recipient sites, newly sutured wounds, abrasions, and minor or partial thickness burns. It may also be used as an initial layer in dressing surgical wounds with light exudate.

Product codes

FRO

Device Description

The Dynarex Xeroform Petrolatum Dressing is a sterile, single use, non-adherent dressing consisting of non-woven absorbent gauze saturated with Xeroform with 3% Bismuth Tribromophenate in a petrolatum blend. Packaged in paper metalized chevron pouches and available in Sizes: 2" x 2" ( Item #: 3051), 1" x 8" ( Item #: 3052), 4" x 4" ( Item #: 3053), 5" x 9" ( Item #: 3054).

Dynarex Xeroform Petrolatum Dressing gauze is a type of medical dressing and has ingredients finely wovens mesh medical gauze infused with a blend of petrolatum and 3% Bismuth Tribromophenate. Dynarex Xeroform Petrolatum Dressing use is as a primary contact layer in dressing wounds such as lacerations, skin graft recipient sites, newly sutured wounds, abrasions, and minor or partial thickness burns.

Gauze saturated with a moist or wet ointment is normally used to maintain a healthy and hydrated wound bed so that wounds can heal effectively and dressings can be changed without causing unnecessary discomfort. One of the substances the Dynarex Xeroform Dressing is saturated with is the petroleum-derived, gelatinous substance petrolatum.

When applied to a non-draining or lightly draining wound, Dynarex Xeroform Petrolatum Dressing provides a moist environment, conducive to wound healing.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Wounds such as lacerations, skin graft recipient sites, newly sutured wounds, abrasions, and minor or partial thickness burns.

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Not Found

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K973507

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

N/A

0

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of a human figure with three faces in profile, one behind the other, with flowing lines representing the body.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

October 3, 2016

Dynarex Corporation Mr. James Hurlman Manager Regulatory Affair 10 Glenshaw Street Orangeburg, New York 10962

Re: K152970

Trade/Device Name: Dynarex Xeroform Petrolatum Dressing Regulatory Class: Unclassified Product Code: FRO Dated: August 29, 2016 Received: September 2, 2016

Dear Mr. Hurlman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

1

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

David Krause -S

for

Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

2

Indications for Use

510(k) Number (if known) K152970

Device Name Dynarex Xeroform Petrolatum Dressing

Indications for Use (Describe)

Dynarex Xeroform Petrolatum Dressing is intended for use as a primary contact layer in dressing wounds such as lacerations, skin graft recipient sites, newly sutured wounds, abrasions, and minor and partial thickness burns. It may also be used as an initial layer in dressing surgical wounds with light exudate.

Type of Use (Select one or both, as applicable)

|X Prescription Use {Part 21 CFR 801 Subpart D}

| Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Form Approved: OMB No, 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

3

Image /page/3/Picture/0 description: The image shows the word "dynarex" in bold, black letters. The letters are sans-serif and have a slight drop shadow effect, giving them a three-dimensional appearance. The word is centered and takes up most of the frame, with a white background providing contrast.

September 23, 2016

Food and Drug Administration Center for Devices and Radiological Health Document Control Center - WO66-G609 10903 New Hampshire Avenue Silver Spring, Maryland 20993-0002

Re: 510 (k) Notification - Traditional

Dear Sir / Madam:

In accordance with Section 510(k) of the Federal Food, Drug and Cosmetic Act, and in conformance with 21 CFR Part 807, pre-market notification is hereby given of the intention of Dynarex Corporation to intorstate commerce for commercial distribution a sterile Xeroform Petrolatum Dressing.

The following is being submitted in conformance with 21 CFR Part 807.87:

| 1. Applicant | Dynarex Corporation
10 Glenshaw Street
Orangeburg, NY 10962
USA |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2. Initial Importer | Dynarex Corporation
10 Glenshaw Street
Orangeburg, NY 10962
USA |
| Registration No. | 2431014 |
| 3. Contact Person | James Hurlman
Official Correspondent / Dynarex Corp
10 Glenshaw Street
Orangeburg, NY 10962
PH: 845-365-8200 Ext 6616
Fax: 845-680-6717
E-mail: j.hurlman@dynarex.com |
| Alternate Only | Mr. Zalman Tenenbaum
President / CEO / Dynarex Corp
10 Glenshaw Street
Orangeburg, NY 10962
PH: 845-365-8200 Ext 6425
Fax: 845-365-8201
E-mail: z.tenenbaum@dynarex.com |

4

Image /page/4/Picture/0 description: The image shows the word "dynarex" in a bold, sans-serif font. The letters are black and have a slight drop shadow effect, giving them a three-dimensional appearance. The word is presented in all lowercase letters and is centered on a white background.

  • Device Proprietary Trade Name Dynarex Xeroform Petrolatum Dressing 4.
  • న్. Manufacturer

Roosin Medical Co. Ltd No. 8 Yuandong Road, Kouan Town Gaogang, Taizhou, Jiangsu, China 225321

    1. Factory Address Same as Manufacturer.
    1. Listing & Registration Information Roosin Medical Co. Ltd Reg. No .: 3007124979
    1. Device Class
    1. Classification No.

Product Code: FRO

structive Surgery Devices

Unclassified, Div. Surg. Devices Plastic and Recon-

10. Identification of Equivalent Marketed Device

Dynarex would like to claim substantial equivalence to the following device already being marketed in interstate commerce:

Description: Classification Name: Unclassified Common or Usual Name: Xeroform Petrolatum Wound Dressing

Product Code510(k) NumberTrade NameManufacturer
FROK973507Kendall Xeroform
Petrolatum Wound
DressingKendall Healthcare Products
Company

Statement of Similarities and / or Differences with Marketed Device.

Dynarex Xeroform Petrolatum Dressing is substantially equivalent in safety and effectiveness to Kendall Healthcare Products Company Kendall Xeroform Petrolatum Wound Dressing.

5

Image /page/5/Picture/0 description: The image shows the word "dynarex" in bold, black letters. The letters are sans-serif and have a slight drop shadow effect, giving them a three-dimensional appearance. The word is centered and takes up most of the frame, with a white background.

11. Indications for Use Statement

Dynarex Xeroform Petrolatum Dressing is intended for use as a primary contact layer in dressing wounds such as lacerations, skin graft recipient sites, newly sutured wounds, abrasions, and minor or partial thickness burns. It may also be used as an initial layer in dressing surgical wounds with light exudate.

12. 510(k) Summary

This document serves as our "510(k) Summary", our summary of safety and effectiveness information upon which our equivalence determination is based.

13. Description of Product

  • a) Classification: FDA's Division of Surgical Devices (DSD) Plastic and Reconstructive Surgery Devices Branch Two - Skin/Wound Dressing/Aesthetic Injectables (PRSB2) devices as Unclassified -Pre-Amendment, General and Plastic Surgery, Classification Code FRO.
  • b) Device Description: The Dynarex Xeroform Petrolatum Dressing is a sterile, single use, non-adherent dressing consisting of non-woven absorbent gauze saturated with Xeroform with 3% Bismuth Tribromophenate in a petrolatum blend. Packaged in paper metalized chevron pouches and available in Sizes: 2" x 2" ( Item #: 3051), 1" x 8" ( Item #: 3052), 4" x 4" ( Item #: 3053), 5" x 9" ( Item #: 3054)

c) Principal of Operation and Conditions of Use:

Dynarex Xeroform Petrolatum Dressing gauze is a type of medical dressing and has ingredients finely wovens mesh medical gauze infused with a blend of petrolatum and 3% Bismuth Tribromophenate. Dynarex Xeroform Petrolatum Dressing use is as a primary contact layer in dressing wounds such as lacerations, skin graft recipient sites, newly sutured wounds, abrasions, and minor or partial thickness burns.

Gauze saturated with a moist or wet ointment is normally used to maintain a healthy and hydrated wound bed so that wounds can heal effectively and dressings can be changed without causing unnecessary discomfort. One of the substances the Dynarex Xeroform Dressing is saturated with is the petroleum-derived, gelatinous substance petrolatum.

When applied to a non-draining or lightly draining wound, Dynarex Xeroform Petrolatum Dressing provides a moist environment, conducive to wound healing.

6

Image /page/6/Picture/0 description: The image shows the word "dynarex" in bold, black letters. The font is sans-serif and the letters are closely spaced together. There is a slight shadow effect behind the letters, giving them a 3D appearance. The background is plain white.

14. Description of Specific Standards Used for the Dynarex Xeroform Petrolatum Dressing Which Describe the Physical Properties of the dressing.

Standard methods for the manufacture of the Dynarex Xeroform Petrolatum Dressing are utilized by the manufacturer. The Certificates of Analysis showing the standards / testing referenced by the manufacturer which would define the physical properties of the petrolatum and 3% bismuth tribromophenate used in the device manufacturing are attached.

15. Quality Assurance Testing

The quality system is operated and maintained under FDA/QSR CFR21 Part 820 and ISO 13485 guidelines. Documented testing procedures are in place. Initial inspection has visual characteristics such as appearance of mixed ingredients, coating, cutting edges and size and heat sealing testing. Final inspection includes these tests and additional weight and count inspection testing on the finished device to demonstrate the device meets its defined specifications. Dynarex Corporation additionally inspects the product upon arrival for final release.

Standards used:

AAMI/ANSI/ISO 10993-1 Biological Evaluation of Medical Devices - Part 1 Evaluation and Testing Parts 3, 4, 5, 10, 11 2009 (R) 2013

ISO 11137-2 Sterilization of Healthcare Products - Radiation - Part 2 - Dose Method 1 2013

16. Standard Operating Procedures as Applied to the Manufacture of the Dynarex Xeroform Petrolatum Dressing

Standard operating procedures (SOP's) are in place for the manufacturing and assembly portions of the manufacturing such as Machine Set-Up, Process Control, Initial Testing, On-line visual testing (Roaming Inspector) and final inspection.

17. Sterilization Validation / Routine Processing

The dressing is a sterile device via gamma radiation per ISO 11137-2: 2013 to a 106 SAL.

18. Dynarex Xeroform Petrolatum Dressing Biocompatibility

Biocompatibility Testing Matrix: Surface Device, Prolonged [≤ 24 hrs to ≤30 days], Breached / Compromised.

Biocompatibility The device meets all of the requirements, as applicable, to ISO 10993-3: 2014 Genotoxicity ISO 10993-4: 2006 / ASTM F756: Hemolysis, ISO 10993-5:2009 Cytotoxicity, ISO 10993-10: 2010 Skin Sensitization and Primary Skin Irritation. ISO 10993-11: 2006 Systemic Toxicity,

19. Shelf Life / Expiration Dating

Dynarex is claiming a 3 year shelf life / expiration dating.

20. Labeling / Special Labeling Claims

Labeling samples for the device pouch, box and insert are attached.

7

Image /page/7/Picture/0 description: The image shows the word "dynarex" in bold, black letters. The letters are sans-serif and have a slight drop shadow, giving them a 3D effect. The word is centered and takes up most of the frame.

CORPORATION

10 Glenshaw Street, Orangeburg, N.Y. 10962

It is understood from the predicate devices 510k letter of substantial equivalence that the Dynarex Xeroform Petrolatum Dressing product has the following limitations;

    1. This device may not be labeled for use on 3rd degree burns.
    1. This device may not be labeled as having an accelerating effect on the rate of wound healing or epithelization.
    1. This device may not be labeled as a long-term, permanent, or no-change dressing, or as an artificial (synthetic) skin.
    1. This device may not be labeled as a treatment or a cure for any type of wound.

Table 1

TABLE OF COMPARISON

| CHARACTERISTIC | | APPLICANT DEVICE
DYNAREX XEROFORM
PETROLATUM DRESSING | PREDICATE DEVICE
KENDALL XEROFORM
PETROLATUM DRESSING |
|---------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indication for Use | | Dynarex Xeroform Petrolatum Dressing is
intended for use as a primary contact layer
in dressing wounds such as lacerations,
skin graft recipient sites, newly sutured
wounds, abrasions, and minor or partial
thickness burns. It may also be used as an
initial layer in dressing surgical wounds
with light exudate. | Is intended for use as a primary contact
layer in dressing wounds such as
lacerations, skin graft recipient sites,
newly sutured wounds, abrasions, and
minor or partial thickness burns. It may
also be used as an initial layer in dressing
surgical wounds with light exudate where
mild medication and deodorization are
desired. |
| Device
Materials | Substrate | Cotton Gauze | Cotton Gauze |
| | Material 1 | 3% Bismuth Tribromophenate | 3% Bismuth Tribromophenate |
| | Material 2 | Petrolatum | Petrolatum |
| Single Use | | Yes | Yes |
| Color | | Yellowish | Yellowish |
| Dimensions | | 1x8"/2x2"/4x4"/5x9" | 1x8"/2x2"/4x4"/5x9"/4"x3yds |
| Sterility | | Sterile ISO 11137-2: 2013 to a 106 SAL | Sterile ISO 11137-2: 2013 to a 106 SAL |
| Pouch Packaging | | PET / ALPET / PE | Metalized chevron pouches |

In summary. Dynarex Xeroform Petrolatum Dressing meets the same biocompatibility requirements per ISO 10993-3. ISO 10993-4, ISO 10993-5, ISO 10993-10 and ISO 10993-11 as our predicate device. Also, it's physical and performance meets requirements of it's pre-defined acceptance criteria for intended uses as the predicate device. All dressings are sterilized by radiation using conditions validated following ISO 11137-2: 2013 to a 10°SAL as the predicate device.

21. Substantial Equivalent Statement

Based on the comparisons stated above of the intended use, design, materials and performance, our Dynarex Xeroform Petrolatum Dressing is substantially equivalent to its predicate device.